Preliminary evidence from a multicenter prospective observational study of the safety and efficacy of chloroquine for the treatment of COVID-19

• 作者: Bei Zhong Binghui Chen Changqing Lin Duanqing Pei Fei Xiao Guanmin Jiang Hong Shan Huili Chen Jiabi Liang Jianhua Feng Jianhui Zhou Jing Liu Jingfen Xiang Jingxian Shu Jinyu Xia Lin Tian Man Li Meiwen Tang Mingxing Huang Nanshan Zhong Pengfei Pang Ruilin Sun Shanping Jiang Shaoxuan Liu Songmei He Tiantian Tang Wenxin Hong Xiaohua Wang Yang Li Yaocai Li Yingying You Yinong Ye Zhaoqin Wang Zhilong Wu Zhonghe Li Zhongsi Hong
• 来源期刊: 国家科学评论（英文版）
• 年，卷（期）: 2020,（9）
• 所属期刊栏目: RESEARCH ARTICLES
• 页码范围: 1428-1436
• 页数: 9页
• 语种: 英文
• DOI: 10.1093/nsr/nwaa113

摘要

Effective therapies are urgently needed for the SARS-CoV-2 pandemic.Chloroquine has been proved to have antiviral effect against coronavims in vitro.In this study,we aimed to assess the efficacy and safety of chloroquine with different doses in COVID-19.In this multicenter prospective observational study,we enrolled patients older than 18 years old with confirmed SARS-CoV-2 infection excluding critical cases from 12 hospitals in Guangdong and Hubei Provinces.Eligible patients received chloroquine phosphate 500 mg,orally,once (half dose) or twice (full dose) daily.Patients treated with non-chloroquine therapy were included as historical controls.The primary endpoint is the time to undetectable viral RNA.Secondary outcomes include the proportion of patients with undetectable viral RNA by day 10 and 14,hospitalization time,duration of fever,and adverse events.A total of 197 patients completed chloroquine treatment,and 176 patients were included as historical controls.The median time to achieve an undetectable viral RNA was shorter in chloroquine than in non-chloroquine (absolute difference in medians-6.0 days;95％ CI -6.0 to-4.0).The duration of fever is shorter in chloroquine (geometric mean ratio 0.6;95％ CI 0.5 to 0.8).No serious adverse events were observed in the chloroquine group.Patients treated with half dose experienced lower rate of adverse events than with full dose.Although randomized trials are needed for further evaluation,this study provides evidence for safety and efficacy of chloroquine in COVID-19 and suggests that chloroquine can be a cost-effective therapy for combating the C OVID-19 pandemic.